Re: Early Unblinding in Phase III

From: Cornelia Weber 41 61 68 88017 <CORNELIA.WEBER@roche.com> Subject: Re: Early Unblinding in Phase III Date: 22 Jul 1997 06:22:51 -0400 Dear all, I am clinical pharmacologist at Hoffmann-La Roche Ltd., Basel, Switzerland, and responsible for a project in the cardiovascular area. I am planning to start population PK analysis for a phase III study before actual data base closure. That means, that certain individuals (the ones performing the population analysis which doesn't necessarly include myself) would have to be unblinded or would have to work with recoded data (although demographic data etc. would theoretically allow the identification of individual patients) at a stage when the pivotal phase III trial is still running. As time is critical for everybody working in industry I would assume that there are people outside - in other companies - having already experience how to achieve such a goal and whether this created any difficult situation with regulatory authorities concerning the validity of the trial. I would of course very much appreciate to get some feedback from some people working at regulatory agencies. It goes without saying that the rest of our clinical team is very concerned not to jeopardize the credibility of the trial in the perspective of regulatory agencies. Thank you all in advance Conni Weber, Ph.D.